Why the study?
Obesity drives endothelial dysfunction and adipose tissue inflammation, with MPO-releasing myeloid cells accumulating in PVAT, but MPO's role in altering PVAT and vascular function remained to be defined.
Does MPO reduction improve endothelial function and reduce perivascular adipose tissue inflammation in obesity?
Does MPO reduction improve endothelial function and reduce perivascular adipose tissue inflammation in obesity?
Myeloperoxidase links obesity to vascular dysfunction by driving perivascular adipose tissue inflammation, and its reduction improves endothelial function.
MPO reduction may improve endothelial function in obesity; leaves open whether targeting MPO alters clinical cardiovascular outcomes.
Obesity, a main driver of cardiovascular morbidity, contributes to endothelial dysfunction and inflammation in adipose tissues. Perivascular adipose tissue (PVAT) surrounds arteries and influences vascular function. In obesity, immune cells, including myeloperoxidase (MPO)-releasing myeloid cells, accumulate in PVAT. In this study, we show MPO levels to correlate with body weight and endothelial function in obese patients ( n = 33) and mice. In addition, MPO deficiency reduces immune cell frequency, enhances PVAT beiging via soluble guanylyl cyclase β1 (sGC-β1), and increases oxygen consumption in vivo . Further, nitrotyrosine formation and inflammatory cytokine release are attenuated in obese Mpo −/− mice. Mechanistically, adiponectin (APN) secretion improves endothelial function and reduces arterial stiffness. In vitro , MPO-treated human white adipocytes show lower APN and brown adipocyte marker expression but increased inflammation. Thus, MPO impairs vascular function via PVAT inflammation and suppression of vasoprotective mediators, making it a potential therapeutic target in obesity-related cardiovascular disease. • MPO is associated with endothelial dysfunction in obese patients • MPO induces pro-inflammatory PVAT activation and immune cell abundance • MPO suppresses PVAT beiging via sGC-β1 inhibition, thereby reducing oxygen consumption • MPO is a potential therapeutic target to prevent cardiovascular disease in obesity Hof et al. show that myeloperoxidase (MPO) links obesity to vascular dysfunction by driving perivascular adipose tissue (PVAT) inflammation. MPO levels correlate with body weight and endothelial dysfunction, while MPO deficiency reduces PVAT inflammation, promotes adipocyte “beiging” via sGC-β1, increases adiponectin secretion, and improves vascular function.
No takes yet. Share an insight, caveat, or question.
Hof et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: